Clinical Medicine Insights: Pathology

A surprising common pathological processes is found between Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM)[1]. AD and T2DM share some common pathological processes: Amyloid β (Aβ), τ hyperphosphoralation, insulin abnormality. Disturbance in insulin signalling is not only involved in blood glucose level but also in numerous degenerative processes. Glucagon-like peptide 1 (GLP-1) has attracted substantial attention for its advantage in treating T2DM. GLP-1 can reduce Aβ levels in brain. All these encourage us in a medical hypothesis: that is, that GLP-1 is a promising agent in the therapy of AD.